# Sermorelin References: The Studies and Reviews Cited on This Site

> Sermorelin references: the full citation list — PubMed-linked studies, trials, and reviews on GHRH(1-29), GH/IGF-1, and body composition — behind every figure on this site.

Every study, trial, and review cited across this site, with DOIs and PubMed links.

## How to read these references

Every numbered citation `[N]` on this site points to an entry below. Where a figure comes from a GHRH analog rather than from sermorelin itself, the page text says so — and you can confirm it here by the study's own title. Several body-composition figures cite tesamorelin trials; that is deliberate and labeled, not a substitution. Links go to PubMed; DOIs are listed for permanent reference.

## References

[1] Granata R, Leone S, Zhang X, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[2] Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[3] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[4] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[7] Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[8] Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. https://pubmed.ncbi.nlm.nih.gov/23015655/
[9] Granata R, Leone S, Zhang X, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. (GHRP/GHS receptor distinction discussed within.) https://pubmed.ncbi.nlm.nih.gov/39537825/
[10] Utz AL, et al. The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators Inflamm. 2010;2010:434562. https://pubmed.ncbi.nlm.nih.gov/20150954/
[11] Vijayakumar A, et al. Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans. Clin Diabetes Endocrinol. 2022;8(1):1. https://pubmed.ncbi.nlm.nih.gov/35101148/
[12] Sigalos JT, Pastuszak AW. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/
[13] Verges B, et al. GHRH in diabetes and metabolism. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39560873/
[14] Gahete MD, et al. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39579280/
[15] Bagno LL, et al. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2023;324(6):H825-H835. https://pubmed.ncbi.nlm.nih.gov/36897749/
[16] Falutz J. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. https://pubmed.ncbi.nlm.nih.gov/22298602/

---

A plain-English reading room that traces the GHRH(1-29) signal from pituitary to IGF-1 — every figure wired back to its study, the fat-loss data tagged as tesamorelin where it belongs, and the missing long-term adult evidence left openly unlit; no clinic behind the console and nothing here dosed, compounded, or sold.